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An overview of recent developments in the
analytical detection of new psychoactive
substances (NPSs)
Jamie P. Smith, Oliver B. Sutcliﬀe and Craig E. Banks*
New psychoactive substances (NPSs), sometimes referred to as “legal highs” in more colloquial environ-
ments/the media, are a class of compounds that have been recently made available for abuse (not
necessarily recently discovered) which provide similar eﬀects to the traditional well studied illegal drugs
but are not always controlled under existing local, regional or international drug legislation. Following an
unprecedented increase in the number of NPSs in the last 5 years (with 101 substances discovered for the
ﬁrst time in 2014 alone) its, occasionally fatal, consequences have been extensively reported in the media.
Such NPSs are typically marketed as ‘not for human consumption’ and are instead labelled and sold as
plant food, bath salts as well as a whole host of other equally nondescript aliases in order to bypass legis-
lative controls. NPSs are a new multi-disciplinary research ﬁeld with the main emphasis in terms of foren-
sic identiﬁcation due to their adverse health eﬀects, which can range from minimal to life threatening and
even fatalities. In this mini-review we overview this recent emerging research area of NPSs and the
analytical approaches reported to provide detection strategies as well as detailing recent reports towards
providing point-of-care/in-the-ﬁeld NPS (“legal high”) sensors.
Introduction
New Psychoactive Substance (NPS) is an umbrella term to
refer to substances which mimic the eﬀects of common illicit
materials (for example, methamphetamine and cannabis)
however they are not controlled by drug legislation such as the
Misuse of Drugs Act1 in the United Kingdom and other similar
controls internationally. Designed, in some cases deliberately,
to evade international control, NPSs may pose a significant
danger to the health and safety of the public. As with con-
trolled substances, NPSs are understood to have potentially
negative short-term side eﬀects such as paranoia, psychosis
and seizures however these may not always be fully understood
on account of the materials often being fairly new and under-
studied, as such their long term health risks are also not
always clearly understood.2 The United Nations Oﬃce on
Drugs and Crime (UNODC) and European Monitoring Centre
for Drugs and Drug Addiction (EMCDDA) standardised the
term “New Psychoactive Substance(s)” and detailed the following
sub-categories: synthetic cannabinoids, synthetic cathinones,
ketamine, phenethylamines, piperazines, plant-based sub-
stances: Khat, Kratom, Salvia divinorum and Miscellaneous:
aminoindanes, phencyclidine, tryptamines.
Given the nature of NPSs underhanded production, purpo-
sely designed to evade international drug legislation, they are
intrinsically marketed and sold as “legal highs”. Easily avail-
able at ‘head shops’ (a commercial outlet selling cannabis and
tobacco paraphernalia), market stalls and the internet;
vendors of NPSs are often operating on the edge of legality by
being both vague and creative in their description of the pro-
ducts contents and its purported uses. NPSs may be sold as
research chemicals, plant food, bath salts, exotic incenses etc.
together with slightly more telling descriptors such as: party
pills, herbal highs and smoking blends although these names
can often be mercurial, for example, mephedrone (a synthetic
cathinone) pre-control was plant food whereas after becoming
a controlled substance it was referred to as a ‘research
chemical’.
Although given these nondescript aliases, NPSs products
often have brand names; examples of “legal high” brand names
are ‘Benzo Fury’, ‘Afghan Incense’, ‘NRG-1’ and ‘NRG-2’. The
name or description given to a NPSs or “legal high” product
may not always pertain to what is the actual psychoactive sub-
stance present, for example mephedrone was detected in pro-
ducts sold as naphyrone or NRG-1 in the UK even after its
ban,3 another survey found 70% of NRG-1 and NRG-2 products
examined contained mixtures of substituted cathinones and
Faculty of Science and Engineering, School of Science and the Environment, Division
of Chemistry and Environmental Science, Manchester Metropolitan University,
Chester Street, Manchester M1 5GD, UK. E-mail: c.banks@mmu.ac.uk;
Fax: +44 (0)1612476831; Tel: +44 (0)1612471196
4932 | Analyst, 2015, 140, 4932–4948 This journal is © The Royal Society of Chemistry 2015
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
2 
Ju
ne
 2
01
5.
 D
ow
nl
oa
de
d 
on
 3
1/
12
/2
01
5 
08
:5
1:
07
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
View Journal  | View Issue
not, at the time uncontrolled, naphyrone.4 Clearly there are no
assurances to the customer of these NPS products that the con-
tents are the same as advertised, furthermore they may be
unwittingly violating drug legislation as the contents within
are controlled substances.
Abuse of NPSs has been reported to be increasing since
ca. 2009 and has continued to be an ever growing market5
emerging at an unprecedented rate something also reflected in
the online marketplace with the number of online vendors in
the UK increasing by more than 300% between 2010 and
2011.6 New materials made available for abuse appear rapidly
and, at times, can gain a ‘foothold’ in the market – such as
mephedrone. In 2014, 101 new substances were reported for
the first time to the EU early warning system (EWS) run by the
EMCDDA up from 81 in 2013 which is also an increase from
the 74 substances notified in 2012.7 Of the findings of the
EWS synthetic cannabinoids are the most frequently discov-
ered with 102 detected between 2005 and 2013. A graphical
representation of NPSs notified to the EWS between 2005–2014
is shown in Fig. 1.7
The media has reported on numerous deaths related to
“legal highs” and given the wide variety of NPS and the ever-
changing composition of existing products, a completely new
field of research has emerged in the continual development of
analytical techniques along with presumptive tests and in-the-
field sensors. To date, there are reviews on the chemistry,
pharmacology and toxicology of NPSs but no comprehensive
review of the current techniques for the analysis of these sub-
stances has, to-date, been compiled.
In this mini-review a thorough overview of this new analyti-
cal field of NPSs is provided which covers: synthetic cannabi-
noids (most frequently discovered NPS by the EWS), synthetic
cathinones; particularly mephedrone (amidst reports by the
Crime Survey for England and Wales [CSEW] detailing
mephedrone as the most prevalent of abused NPSs) and in
lesser detail pieces of interesting research of the other NPSs
notified to the EWS (visible in Fig. 1).7
Synthetic cathinones
Synthetic cathinones are an amphetamine-like cheap alterna-
tive to Ecstasy derived from cathinone; an organic stimulant
found in Khat – a plant native to East Africa and the Middle-
East and they possess pharmacological similarity to the phen-
ethylamine class of psychoactives (e.g. amphetamine and
methamphetamine). The eﬀects of synthetic cathinones on the
body are reported to have both cardiovascular and neurological
side-eﬀects; believed to block the reuptake of norepinephrine,
dopamine and serotonin8 whilst there are also reports that
they also induce the release of more dopamine9 suggesting
synthetic cathinones act like both methamphetamine and
cocaine synchronously.8–12
Internationally there has been a tightening of the legis-
lation regarding synthetic cathinone derivatives, for example,
cathinones are illegal in the UK as well as Germany, The
United States, Canada and many others.13,14 The European
Monitoring Centre for Drugs and Drug Addiction’s (EMCDDA)
Early Warning System (EWS) has reported 74 new synthetic
cathinones between 2005 and 2014, with 30 new substances
discovered in the year 2014 alone (Fig. 1). Clearly, the epidemic
initiated by synthetic cathinones is showing no signs of cessa-
tion within the near future hence the development of methods
for their detection and quantification is timely and urgently
Fig. 1 A graphical representation of new psychoactive substances notiﬁed to the EWS between 2005–2014. Reproduced from ref. 7 with per-
mission of the EMCDDA.
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required. Mephedrone in particular, since it’s availability for
abuse, is popular amongst users of “legal high” products and
despite its classification in 2009 reports from the Crime Survey
for England and Wales (CSEW) reveal mephedrone was still
being abused in England and Wales in 2014.
Popularly known as ‘bath salts’, ‘research chemicals’ or
‘plant food’, synthetic cathinones are sold under, often
mercurial, non-descript brand names such as ‘Energy’ (NRG),
Blizzard and Ivory Snow containing warning labels such as
‘not for human consumption’ or ‘not tested for hazards or tox-
icity’ in an attempt to bypass legislative controls. The active
component in a “legal high” product can vary wildly, even
within the same brand name;3,10,15 there are no clear assur-
ances to the customer of these NPS products that the contents
are the same as advertised (see introduction).
The list of case reports concerning synthetic cathinone-
induced intoxication is extensive and ever increasing. In the
United States the number of calls to emergency centres, as a
result of synthetic cathinone abuse, increased from 303 to
6100 between 2010 and 2011. A plethora of case reports are
reported in the literature and media spanning a sizeable age
range, including both of the sexes and include fatalities as well
as the curious report of the murder of a goat whilst dressed in
lingerie.16 For instance, a female aged 15 had symptoms of
nausea, vomiting, altered mental status, euvolaemic hypo-
osmotic hyponatremia with encephalopathy and increased
intracranial pressure – mephedrone metabolites were found in
her urine.17 A male aged 31 after admitting to taking three
1500 mg packets of “bath salts” and was reported to have
hallucinations, paranoia, agitation; elevated serum CPK level,
hyperkalemia, dehydration, rhabdomyolysis and acute renal
failure.
Considering all the synthetic cathinones discovered, there
can be no assertions to which are the being abused but what is
evident from the literature is that the most prominent syn-
thetic cathinones found within “legal high” products globally
are mephedrone (4′-methylmethcathinone; 4-MMC) and 3′,4′-
methylenedioxypyrovalerone (MDPV).15 Mephedrone is more
prevalent in Europe and MDPV in the United States;15 a list of
the most prevalent cathinone derivatives18 abused worldwide
can be found in Table 1 although the focus of the review
will apply generally towards the detection and quantification
of mephedrone.
Studying the patterns of NPS abuse can be diﬃcult as it is
frequently based upon self-reported user surveys.19 This is
potentially problematic as in many instances users are, due to
poorly labelled products (see earlier), not in fact aware of the
substances they are taking. In light of this, numerous groups
are making advances towards screening the current NPSs
being abused. A number of revered groups using a range of
chromatographic techniques including high performance-
liquid chromatography (HPLC) and gas chromatography-mass
spectrometry (GC-MS), with LC-MS methods seemingly the
preferred and established technique of choice, have published
exhaustively upon the laboratory-based analysis of synthetic
cathinones,3,20–40 phase I and II metabolites41,42 and more
recently, in light of the often nonenantioselective NPS syn-
thesis, chiral separation of racemic mixtures.43
In 2014 Archer et al.19 analysed urine samples collected
from a night club over one weekend. The manuscript with its
real and imaginative title, “Taking the Pissoir – a novel and
reliable way of knowing what drugs are being used in nightclubs”,
reported the detection of classical recreational drugs and NPSs
such as: mephedrone, 3′-trifluoromethylphenylpiperazine and
2-aminoindane using various chromatographic and mass
spectrometric methods.19 Furthermore parent drug/metabolites
were also detected for amphetamine, cocaine, ketamine, 3′,4′-
methylenedioxymethamphetamine (MDMA), mephedrone and
3-trifluoromethylphenylpiperazine (3-TFMPP); this is impor-
tant as it indicates drugs were being used and not simply dis-
carded into the urinal.19 In the same year, Leﬄer et al.44
(located in the United States) analysed 14 separate street
samples wherein 10 synthetic cathinones were identified
employing a variety of techniques, including gas chromato-
graphy with mass spectrometric detection (GC-MS) and flame
ionization (GC-FID).44 HPLC direct infusion tandem mass
spectrometry (MS/MS) was also used to identify compounds
which were not available as reference materials. Out of the syn-
thetic cathinones detected: 3′,4′-methylenedioxypyrovalerone
(MDPV), 3′,4′-methylenedioxy-α-pyrrolidinobutiophenone
(MDPBP), 4′-fluoromethcathinone (4-FMC), butylone, mephe-
drone, naphyrone, 4′-methylethcathinone (4-MEC), ethcathi-
none, α-pyrrolidinopentiophenone (α-PVP), and 3′-methyl-
α-pyrrolidinopropiophenone (3-MPPP). MDPV was the most
prevalent, found in five of the 14 samples and ranging from
11% to 73% (w/w) between samples.44
Earlier reports in Denmark, Pedersen et al.35 presented an
automated solid-phase extraction (SPE) and ultra-high-
performance liquid chromatography (UHPLC) with time of
flight-mass spectrometry (TOF-MS) screening method for 256
illicit compounds in blood and 95 of these compounds were
validated with regard to matrix eﬀects, extraction recovery,
and process eﬃciency with the limit of detection (LOD)
ranging from 0.001 to 0.1 mg kg−1.35 Application of the
technique to the analysis of 1335 forensic traﬃc cases revealed
992 cases (74%) were positive for one or more traﬃc-relevant
drugs above the Danish legal limits. Commonly abused drugs
such as amphetamine, cocaine, and frequent types of benzo-
diazepines were the major findings. Nineteen less frequently
encountered drugs were detected: buprenorphine, butylone,
cathine, fentanyl, lysergic acid diethylamide, m-chlorophenyl-
piperazine, MDPV, mephedrone, 4′-methylamphetamine, p-
fluoroamphetamine, and p-methoxy-N-methylamphetamine.35
Even as early as 2011, there have been numerous attempts
at constructing screening methods for substituted cathinones
in a number of diﬀerent matrices, Bell and co-workers29
reported a rapid multi-analyte direct urinalysis LC-MS/MS
screening method being able to detect eight analytes includ-
ing; 4′-methylmethcathinone (mephedrone), 3′,4′-methyl-
enedioxymethcathinone (bk-MDMA, ‘methylone’), 4′-methoxy-
methcathinone (bk-PMMA, ‘methedrone’) and 3′,4′-methylene-
dioxypyrovalerone (MDPV).29 Using a dilution of 1 part urine
Minireview Analyst
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to 4 mobile phase to reduce matrix eﬀects and although not
all compounds were completely chromatographically resolved,
there was suﬃcient specificity to allow target analyte identifi-
cation. All the analytes were readily detected at a concentration
of 500 ng mL−1 oﬀering an attractive method for the routine
screen of NPSs.29 The global impact of synthetic cathinones is
compounded when substances such as mephedrone and
MDPV have been detected following sewage-based epidemio-
logy in Chinese ‘megacities’.45
In terms of quantification, Santali et al. provided the first
fully validated HPLC method for the quantification of mephe-
drone22 where limits of detection and quantification of 0.1
and 0.3 µg mL−1 respectively were reported. Khreit et al.
further refined this method enabling the detection of both
mephedrone and two novel derivatives, 4′-methyl-N-ethylcathi-
none (4-MEC) and 4′-methyl-N-benzylcathinone (4-MBC), in
seized samples of “NRG-2”. In this case the limits of detection
and quantification were reported as 0.03 and 0.08 for 4-MEC
and 0.05 and 0.14 μg mL−1 for 4-MBC both in their pure form
and in the presence of common adulterants such as caﬀeine
and benzocaine.3,23 There has also been work using chromato-
graphic methods on the detection of cathinone based “legal
Table 1 List of the most common synthetic cathinones, recreated from ref. 18 with permission of DovePress
Usual names Chemical name
Amfepramone or diethylpropion 2-Diethylamino-1-phenyl-1-propanone
Benzedrone or 4′-methyl-N-benzylcathinone or 4-MBC 1-(4-Methylphenyl)-2-benzylamino-1-propanone
BMDB 2-Benzylamino-1-(3,4-methylenedioxyphenyl)-1-butanone
BMDP or 3,4-MDBC 2-Benzylamino-1-(3,4-methylenedioxyphenyl)-1-propanone
Brephedrone or 3′-bromomethcathinone or 4-BMC 1-(4-Bromophenyl)-2-(methylamino)-1-propanone
Buphedrone 2-(Methylamino)-1-phenyl-1-butanone
Bupropion 1-(3-Chlorophenyl)-2-(tert-butylamino)-1-propanone
Butylone or bk-MBDB 2-(Methylamino)-1-(3,4-methylenedioxyphenyl)-1-butanone
Cathinone 2-Amino-1-phenyl-1-propanone
Dibutylone or methylbutylone or bk-DMBDB 2-(Dimethylamino)-1-(3,4-methylenedioxyphenyl)-1-butanone
Dimethylone or bk-MDDMA 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)-1-butanone
3′,4′-dimethylmethcathinone or 3,4-DMMC 1-(3,4-Dimethylphenyl)-2-(methylamino)-1-propanone
Ephedrone or methcathinone 2-(Methylamino)-1-(4-ethylphenyl)-1-propanone
Ethylbuphedrone or NEB 2-(Ethylamino)-1-phenyl-1-butanone
Ethylcathinone or ethcathinone or ethylpropion 2-(Ethylamino)-1-phenyl-1-propanone
4′-ethylmethcathinone or 4-EMC 2-(Methylamino)-1-phenyl-1-propanone
Ethylone or bk-MDEA 2-(Ethylamino)-1-(3,4-methylenedioxyphenyl)-1-propanone
Eutylone ou bk-EBDB 1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)-1-butanone
Flephedrone or 4′-fluoromethcathinone or 4-FMC 2-(Methylamino)-1-(4-fluorophenyl)-1-propanone
Fluorocathinone or 4-FC 2-Amino-1-(4-fluorophenyl)-1-propanone
Fluoromethcathinone or 3-FMC 2-(Methylamino)-1-(3-fluorophenyl)-1-propanone
Isoethcathinone 2-(Ethylamino)-1-phenyl-2-propanone
Isopentedrone 2-(Methylamino)-1-phenyl-2-pentanone
MDMPP 1-(3,4-Methylenedioxyphenyl)-2-methyl-2-pyrrolidinyl-1-propanone
MDPBP 1-(3,4-Methylenedioxyphenyl)-2-(1-pyrrolidinyl)-1-butanone
MDPPP 1-(3,4-Methylenedioxyphenyl)-2-(1-pyrrolidinyl)-1-propanone
MDPV or MDPK 1-(3,4-Methylenedioxyphenol)-2-pyrrolidinyl-1-pentanone
Mephedrone or 4′-methylmethcathinone or 4-MMC 2-(Methylamino)-1-(4-methylphenyl)-1-propanone
Metamfepramone or dimethylcathinone or dimethylpropion 2-Dimethylamino-1-phenyl-1-propanone
Methedrone or 4′-methoxymethcathinone or bk-PMMA 1-(4-Methoxyphenyl)-2-(methylamino)-1-propanone
Methylbuphedrone or 4-Me-MABP or bk-N-methyl-4-MAB 2-(Methyllamino)-1-(4-methylphenyl)-1-butanone
4′-methyl-N-ethylcathinone or 4-MEC 2-(Ethylamino)-1-(4-methylphenyl)-1-propanone
3′-methylmethcathinone or 3-MMC 2-(Methylamino)-1-(3-methylphenyl)-1-propanone
Methylone or MDMC or bk-MDMA 2-Methylamino-1-[3,4-methylenedioxyphenyl]-1-propanone
MOPPP 4′-Methoxy-α-pyrrolidinovalerophenone
MPBP 1-(4-Methylphenyl)-2-(1-pyrrolidinyl)-1-butanone
MPHP 4′-Methyl-α-pyrrolidinovalerophenone
MPPP 4′-Methyl-α-pyrrolidinovalerophenone
Naphyrone 1-Naphthalen-2-yl-2-pyrrolidin-1-yl-1-pentanone
Propylbutylone or bk-PBDB 2-(Propylamino)-1-(3,4-methylenedioxyphenyl)-1-butanone
Pentedrone or ethyl-methcathinone 2-(Methylamino)-1-phenyl-1-pentanone
Pentylone 2-(Methylamino)-1-(3,4-methylenedioxyphenyl)-1-pentanone
PBP 1-Phenyl-2-(1-pyrrolidinyl)-1-butanone
PEP 1-Phenyl-2-(1-pyrrolidinyl)-1-heptanone
PPP 1-Phenyl-2-(1-pyrrolidinyl)-1-propanone
PVP 1-Phenyl-2-(1-pyrrolidinyl)-1-pentanone
Pyrovalerone 11-(4-Methylphenyl)-2-(1-pyrrolidinyl)-1-pentanone
2′,4′,5′-trimethoxymethcathinone or 2,4,5-TMMC 2-(Methylamino)-1-(2,4,5-trimethylphenyl)-1-propanone
Analyst Minireview
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highs” in biological matrices24,37 in which Beyer et al. were able
to detect and quantify 25 designer cathinones in a validated
LC-MS-MS method.37
Other work26 has seen an attempt to screen chronic abuse
of mephedrone through GC-MS analysis of hair. The hair was
first decontaminated in methylene chloride and incubated
overnight in a pH 7 buﬀer in the presence of deuterated
MDMA at 40 degrees Celsius. The work saw 67 hair specimens
tested for mephedrone with 13 yielding positive results of con-
centrations ranging from 0.2–313.2 ng mg−1.26 The work
showed that like other stimulant drugs, mephedrone is well
incorporated into hair and the analytical method reported
appears sensitive enough to reveal occasional to regular use of
mephedrone.26
Recently direct analysis in real time mass spectrometry
(DART-MS) has been utilised to quantify and characterise the
multitude of new and emerging NPSs.46 Solid synthetic cathi-
none samples (2-FMC, 2-MEC, 2-FEC and 2-EEC) were sampled
directly without pre-treatment and positive ion mass spectra
were acquired using a DART-SVP™ ion source interfaced to an
AccuTOF mass spectrometer. Further advancements in this
methodology by the same authors47 has seen the application
of a time-of-flight (TOF) mass analyzer along with in-source
collision-induced dissociation (CID) spectra to provide data for
presumptive analysis of various synthetic cathinones in a
similar fashion to GC-MS analysis.47 The authors scope for this
work is to provide a rapid screening method to quickly respond
to the rapid evolution of designer drugs and the consequent
testing backlogs that develop.46,47 Ion mobility spectrometry
(IMS) has also been applied to the screening of an array of
NPSs within the literature with acceptable results.48,49
Smith et al.50,51 provided an alternative to chromatography
and proposed a novel sensing protocol based upon the electro-
chemical methods. Of note is the reduction of the cathinone
substitutes; mephedrone and 4-MEC with a scope to provide
an on-the-spot analytical screening tool with cyclic voltamme-
try.50 Analysed in pH 4.3 acetate buﬀer, limits of detection
were found to correspond to 11.80 μg mL−1 for 4-MMC and
11.60 μg mL−1 for 4-MEC.50 This work demonstrated for the
first time a rapid, accurate, and sensitive method for the
quantification of synthetic cathinone components found in
seized street “legal high” samples (NRG-2) via the use of an
electrochemical protocol utilizing graphite screen-printed elec-
trodes (GSPEs) which was also independently verified with
HPLC.50
Interesting developments in the detection of synthetic cath-
inone derivatives is the use of surface enhanced Raman-
spectroscopy (SERS) have also been reported.52,53 In this novel
approach, the usually required thin metallic surface (typically
gold or silver) was provided by galvanising a British two pence
coin with silver. Note that a pre-1992 two pence coin (97%
Copper) is required as post-1992 two pence coins are com-
posed of copper-plated steel and have an undefined compo-
sition.52 Fig. 2 shows the concept when dendritic structures
are evident on the two pence surface, demonstrating proof-of-
concept for SERS detection of mephedrone, MDMA and
aminoindane 5′,6′-methylenedioxy-2-aminoindane (MDAI).52
Further developments saw the researchers working towards a
new optimization strategy for the SERS detection of mephe-
drone using a portable Raman system employing a fractional
factorial design approach to significantly reduce the statistical
experiments whilst maintaining statistical integrity.53 Further-
more, four optimised SERS protocols for which the reproduci-
bility of the SERS signal and the limit of detection of
mephedrone were established with an estimated limit of detec-
tion of 1.6 μg mL−1.53
Another alternative to the well-established chromatographic
methods, NPS detection has been reported with the use of
immunochemistry, Paillet-Loilier et al.18 noted the use of this
technique to test the cross-reactivity of some synthetic cathi-
nones using the semi-quantitative AxSYM amphetamine/
methamphetamine II assay in tandem with Fluorescence
Polarization Immunoassay (FPIA). Evaluating the responses
from aqueous solutions of 14 substituted cathinones at 1 mg
L−1, 10 mg L−1 and 100 mg L−1, the authors observe pente-
drone, pentylone, α-pyrrolidinovalerophenone (PVP), and 3′,4′-
methylenedioxypyrovalerone (MDPV) did not react with the
protocol. Some synthetic cathinones, however, reacted in the
assay at 10 mg L−1: ethylone, mephedrone, methylone, methe-
drone, and 4′-methyl-N-ethylcathinone (MEC) scrutiny of this
reveals that each of these that did react had the least substi-
tutions on the ethylamine chain suggesting the method has
limitations to larger molecules.18 Commercially available
enzyme-linked immunosorbent assays have been used to
Fig. 2 Characterisation of galvanic displacement. The optical image
(top left) shows a clean British 2p coin, with silver deposited onto its
surface. (A) Shows an SEM of the rough surface of the two pence after
cleaning. The SEM in (B) shows the silver dendritic structures that are
formed on the coins surface once 10 μL of AgNO3 was left to mature for
20 s at room temperature (23 °C). The fern like structures are magniﬁed
in (C) and show that secondary crystalline domains grow perpendicular
from a primary silver backbone.52 Reproduced from ref. 52 with per-
mission of The Royal Society of Chemistry.
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analyse eight synthetic cathinone derivatives amongst 30
designer drugs.54 The test demonstrated cross-reactivity at con-
centrations at low as 0.15 mg L−1 when tested against the
Randox Mephedrone/Methcathinone ELISA kit (RANDOX
Toxicology, Crumlin, UK), a protocol recently developed for
forensic specific cathinone screening in urine and blood
specimens.54
Presumptive testing of cathinone derivatives was carried
out by Nic Daeid and colleagues40 as per United Nations rec-
ommended guidelines. Various presumptive tests were investi-
gated, however results suggested the Zimmerman test, which
relies on the presence of a carbonyl group in close proximity to
a methyl group on the same molecule and reaction with 2′,4′-
dinitrobenzene to form a Meisenheimer reddish-purple
colour, was the most consistently eﬀective test method. A
small amount of each test sample was placed into a well of a
spotting tile and 2 drops of 1% 2′,4′-dinitrobenzene in metha-
nol followed by 2 drops of 15% potassium hydroxide in water
were added. Any colour change or other noticeable eﬀect
occurring immediately on addition of the reagents was noted
and observations were made again after 5 minutes; Specific
colour changes were observed in all cases apart from bupro-
pion. Nic Daeid et al. have also reported using stable isotopic
fractionation/profiling (isotope ratio mass spectrometry;
IRMS), to provide a potentially quantifiable link between the
precursor (4′-methylpropiophenone) and the illicit drug
product (4′-methylmethcathinone) for a particular manufac-
turer and synthetic route of mephedrone.55
Synthetic cannabinoids
Synthetic cannabinoids emerged as a recreational product
ca. 2008 in the form of aminoalkylindoles such as JWH-018.
They were originally investigated by Professor Huﬀman56
as therapeutic compounds, however they were subsequently
abandoned due to the unwanted psychoactive side eﬀects.
Despite many classes synthetic cannabinoids becoming con-
trolled under drug legislation, there are still many which
remain legal whilst still posing threat to the population. As
with synthetic cathinone derivatives, there is often limited to
no information on the packaging of the products and the
active ingredients present can vary greatly between products of
the same name.57–61 These compounds were first introduced
into products known as ‘K2’ and ‘Spice’ with the latter having
a market range of: Spice Silver, Spice Gold and Spice
Diamond.† The products, advertised as incense or smoking
mixtures, are typically sold consisting of a few grams of finely
cut green/brown plant material as to perhaps replicate the
appearance of cannabis whilst being infused with the active
synthetic cannabinoid component(s). There are instances of
retailers selling the active components as research chemicals
(similarly to synthetic cathinones) which arrive as a crystalline
powder of high purity.61
There are various case reports to support the literature and
media claims that synthetic cannabinoids have psychoactive
eﬀects akin to that of cannabis. Indeed, the components of
Spice and related herbal products have been identified as
aminoalkylindoles originally synthesised by Huﬀman and
Atwood et al. and have demonstrated that JWH-018 is a potent
and eﬀective CB1 receptor agonist.
62
Interesting case reports with regards to the eﬀects of the
Spice epidemic include a report by Schneir et al.,63 who pub-
lished case studies on two women admitted to a San Diego
(USA) emergency department after smoking Spice “Banana
Cream Nuke” – disorientated, feeling unusual and “as if they
did not know where they were”.63 Another report describes three
cases of the eﬀects of Spice,64 all having a negative urine drug
screen whilst exhibiting agitation, paranoia and tachycardia.
Follow up analysis revealed the urine to contain metabolites of
JWH-018 and JWH-073.64 More recent reports also highlight
similar observations in adolescents and young adults after
intoxication with synthetic cannabinoids.65 Vardakou et al.66
have given an overview of other case reports66 and the psycho-
active properties of Spice products and “legal highs”.
Laboratory analysis revealed the active components of first
generation Spice and related products to be, the previously
mentioned, aminoalkylindoles such as JWH-018 and also
cyclohexylphenols such as CP-47 497. As their popularity rose
through sales in so-called ‘head shops’ as well as on the inter-
net, the substances were legislated as illegal in most countries
worldwide;67 the range of active synthetic cannabinoid com-
ponents of first generation Spice products can be observed
in Scheme 1. Note: the aminoalkylindoles (see Scheme 1) are
given the notation of JWH after the academic who first syn-
thesised these compound, Professor J.W. Huﬀman.
Further confirmation of this came at the end of 2008 when
the German company THC Pharma reported JWH-018 was an
active ingredient in Spice products.68 Following on from this
Auwater et al.69 and Uchiyama et al.70 identified and character-
ized the CP 47 497-C8 (see Scheme 1) as its isomer – a syn-
thetic by-product in Spice Silver, Gold and Diamond as well as
in products named ‘Yuctan Fire’ and ‘Sence’ which is reported
to have 5 to 10 times more analgesic potency that
tetrahydrocannibol.71
An interesting paper from the point of view of the medical
staﬀ that have had to deal with the Spice usage patients has a
light-hearted title of: “Spice” girls: Synthetic cannabinoid
intoxication.63 The authors noted that a urine drugs-of-abuse
immunoassay was negative for amphetamines, barbiturates,
benzodiazepines, benzoylecgonine (cocaine metabolite),
methadone and opiates, oxycodone, phencyclidine, propoxy-
phene and tetrahydrocannabinoids. The residue of the
† Ingredients listed on the packaging of products are as follows – Spice Gold: bay
bean, blue lotus, Lion’s Tail, Indian Warrior, Dwarf Skullcap, Maconha brava, Pink
Lotus, Marshmallow, Red Clover, Rose, Siberian motherwort, Vanilla and honey.
Spice Gold Spirit: Leonurus, Cardiaca, Pedicularis, Canadensis, Scutellaria, Latero
flora, Athaea oﬃcinalis, Rosa damascene, Vanilla planifolia. Spice Diamond: Bay
bean, Blue lotus, Lion’s tail, Indian Warrior, Dwarf Skullcap, Maconha brava, Pink
Lotus, Marshmallow, Red Clover, Rose, Siberian motherwort, vanilla, honey, aroma.
Note the lack of any real ingredients (chemical) and no mention of any amino-
alkylindole (JWH compounds) or cyclohexylphenyls (CP compounds)
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Scheme 1 Chemical structures of synthetic cannabinoids found in herbal products such as the spice range,67 scheme reproduced from ref. 67 with
permission from UNODC.
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patient’s Spice product “Banana Cream Nuke” was found to
contain the synthetic cannabinoids JWH-018 and JWH-073
through gas chromatography-mass spectrometry (GC-MS) and
high performance liquid chromatography with ultraviolet
detection (HPLC-UV). The report highlighted the need for
drugs-of-abuse screenings to be able to detect the JWH class of
compounds, particularly within a clinical setting.
In Germany Lindigkeit et al. analysed Spice Gold with a
GC-MS method wherein the herbal mixtures were ground and
put through a two hour Soxhlet extraction with petroleum
ether.58 Analysis revealed the samples contained CP 47 497-C8
and JWH-018 until German health authorities on the
22nd January 2009 prohibited the sale of the active components
found in Spice – from this point JWH-018 was absent from
Spice, however it wasn’t long until a new analogue, JWH-073,
was found to be contained in Spice products.58 Because
the manufacturers of such products can readily change
the active components in Spice, a rapid method of detecting
prohibited compounds in the complex mixtures is highly
sought after.
To this end, Emanuel and co-workers68 reported for the
first time the components of Spice “Gold Spirit” using GC-MS
(following a simple liquid extraction) alongside the analysis
of Spice “Gold” and “Diamond”; at the time the three most
popular Spice products used. Results indicated that Spice
“Gold” contained CP 47 497-C8 along with ethyl vanillin,
α-tocopherol and γ-tocopherol whereas Spice “Diamond” con-
tained caﬀeine, α-tocopherol, γ-tocopherol, palmitic acid along
with CP 47 497-C8 and JWH-018. As for Spice “Gold Spirit”,
JWH-018 and α-tocopherol were found to be present.68
Other work has of course followed on the analysis of Spice
and related herbal products for instance Uchiyama and co-
workers59 who analysed 46 diﬀerent herbal products with
44 having synthetic cannabinoids as determined via GC-MS
and LC-MS. Two major cannabinoids were found; [2-hydroxy-
4-(2-methylnonan-2-yl)phenyl]cyclohexan-1-ol (cannabicyclo-
hexanol) and JWH-018 and the analysis of the herbal product
(amount of NPS per gram) were found to range from 1.1 to
16.9 mg g−1 and 2.0 to 35.9 mg g−1 respectively.59
In addition to the identification of the chemical com-
ponents contained within the Spice product range there is a
need to understand the eﬀects of the synthetic cannabinoids
on the human metabolism. Sobolevsky72 reported for the first
the time, urinary metabolites of JWH-018; clearly highly useful
for the analysis of patients admitted to emergency depart-
ments and for the development of point-of-care tests (see the
story of the “Spice girls” earlier in this mini-review). Using
LC-MS and GC-MS, two main monohydroxylated metabolites
were identified which are almost completely glucuroconju-
gated with minor metabolites such as N-despentyl hydroxy-,
carboxy-, dihydroxy-, and reduced di- and trihydroxy-metab-
olites.72 It should be noted the parent compound (JWH-018)
was reported to not be detected in urine.72 The authors
observed that there are two main metabolites that are valuable
for detection of JWH-018 in post-administration urine and
LC-MS is a more useful technique as minor metabolites can
also be analysed to support analytical findings.72 Diﬀerent
analytical approaches on Spice and related products have been
reported73–78 with literature reporting the presence of new can-
nabimimetic compounds.60,79,80 Following this pioneering
work, there has been a pursuit of studying synthetic cannabi-
noids in urine.81–87 Further work by Moran et al.88 has
extended the work of Sobolevsky72 and validated an LC-MS/MS
method for the quantitation of the human urine metabolites
of JWH-018 and JWH-073. The work highlighted 6 metabolites
for each molecule with the primary metabolites being dis-
tinguishable between JWH-018 and JWH-073. The authors
have also extended this using a solid-phase extraction
approach.89 One criticism of the above work exploring the
metabolites in urine is the limited population studies – clearly
larger studies will be needed to further understand the
pharmacology of synthetic cannabinoids. Other research has
been devised to quantify cannabinoids in serum and
blood.90–94
A diﬀerent strategy has been to analyse cannabinoids in
hair to show long term past consumption.95 To this end,
Hutter et al.96 reported the hair testing of 22 synthetic cannabi-
noids in human hair. The methodology involves a simple
ultrasonication of the hair sample in ethanol and has a limit
of quantification (LOQ) of 0.5 pg mg−1.96 Perhaps more inter-
estingly, synthetic cannabinoids have even been found in the
urine of US athletes (although its use to enhance performance
is questionable.). Urine samples were collected from 5956 ath-
letes and analysed via high performance-liquid chromato-
graphy-tandem mass spectrometry (HPLC-MS) for the presence
of JWH-018, JWH-073 and their metabolites.97 In 4.5% of the
samples, metabolites of both synthetic cannabinoid com-
pounds were detected; metabolites of JWH-018 and JWH-073
(50%), JWH-018 (49%), and only JWH-073 (1%) were detected
in positive samples.
The focus of the research above has focused on laboratory
based instrumentation, rightly so in order to unambiguously
quantify NPSs but as highlighted in the case of the “Spice
girls”, synthetic cannabinoids do not react using tradition THC
immunoassay tests. To this end Arnston et al.98 have designed
two enzyme linked immunosorbent assays for detection of
JWH-018 and JWH-250 in urine. The assay of JWH-018 has sig-
nificant cross reactivity with several synthetic cannabinoids
and their metabolites contrary to the JWH-250 assay which
exhibits limited cross-reactivity. To start, assays are calibrated
at 5 ng mL−1 with the 5-OH metabolite of JWH-018 and the
4-OH metabolite of JWH-250. To validate the method, 114 and
84 samples of urine for JWH-018 and JWH-250 respectively
were used and confirmed by using liquid chromatograph
tandem mass spectrometry (LC-MS/MS) testing for metabolites
of JWH-018, JWH-019, JWH-073, JWH-250 and AM-2201. Accu-
racy was deemed to be greater than 98% with 95% sensitivity
and specificity for both assays.
Another approach of interest is a presumptive test marketed
by “Narcotic Testing Supplies & Equipment Store”.99 The test
works by inserting a small quantity of a suspected sample into
a plastic ampoule containing 25 μL reagent and 150 mg of
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specially treated absorbing crystals (sodium 36%, potassium
iodide 98% and 0.2% ethanol) stirring and comparing the
colour of the liquid to a pre-determined colour chart clearly
visible from Fig. 3 however the specificity of such a screening
test is questionable.99
As components of Spice and related substances become
banned, they are replaced with a compound which exhibits
similar psychoactive properties yet negating the eﬀectiveness
of the newly introduced ban, see the paper: “Spice: A Never
ending story?” for example.58 As such there is an urgent need
for a faster laboratory method; Emanuel et al. reported the use
of solid probe mass spectrometry alleviating the need for any
sample pre-treatment such as liquid–liquid extraction.68 Since
α-tocopherol is always present in the Spice herbs range, the
authors demonstrated that once α-tocopherol was subtracted
from the obtained spectra, the fragmentation patterns of CP
47 497-C8 and JWH-018 become ‘visible’.68 This screening
methodology is useful for the rapid analysis of the prohibited
substances within the Spice product range (as well as related
substances) with a positive response nullifying the need for
any pre-treatment step (such as liquid–liquid extraction) allow-
ing a full quantification via GC-MS or similar approaches i.e.
LC-MS. Work from Lesiak et al.100 has also attempted to
rapidly detect synthetic cannabinoids without the need for
sample preparation with the use of direct analysis in real time
mass spectrometry (DART-MS)100 being able to screen for
AM-2201, JWH-122, JWH-203, JWH-210 and RCS-4.
To highlight the ever moving field of “legal highs” with
respect to synthetic cannabinoids, in October 2012 new
variants were reportedly found where the structures were a
modification of compounds from the 3-naphthoylindole
series57–60,69,70,80,101–107 identified from regular seizures made
by police in Russia and Belarus.101 Shevyrin et al. have
reported on the analytical characterisation of these new class
of synthetic cannabinoids using GC-HRMS, UHPLC-HRMS,
NMR and FT-IR101 providing robust and reliable confirmatory
analytical approaches. Reports from South Korea also high-
light the ever-changing market detailing the diﬀerent synthetic
cannabinoids which have been identified by their National
Forensic Service between 2009–June 2013.108 The authors note
that whilst initially it was largely naphthoylindoles (e.g.
JWH-018, JWH-073), phenylacetylindoles (e.g. JWH-203,
JWH-250), benzoylindoles (e.g. RCS-2, RCS-4) and CP-47 497
derivatives abused; after legislative bans were introduced,
gradually over time, the molecules identified became new,
typically halogenated, substances such as cyclopropylindoles
(e.g. UR-144, XLR-11) and adamantylindoles (e.g. APICA,
APINACA)108 which are represented in Scheme 2.
Following the influx of new compounds, groups worldwide
moved towards their detection. Scheidweiler et al.109 developed
and validated a liquid chromatography-tandem mass spectro-
metric (LC-MS/MS) method for simultaneously quantifying
JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200,
JWH-210, JWH-250, JWH-398, RCS-4, AM-2201, MAM-2201,
UR-144, CP 47 497-C7, CP 47 497-C8 and their metabolites,
and JWH-203, AM-694, RCS-8, XLR-11 and HU-210 parent com-
pounds in urine.109 Previously there were no extensive syn-
thetic quantitative methods reported in the literature until this
work which presented the novel LC-MS/MS protocol quantify-
ing 20 synthetic cannabinoids and 21 metabolites, and semi-
quantifying 12 alkyl–hydroxy-metabolites.109
Continuing from this, another approach towards the
detection of the new generation of synthetic cannabinoid
agonist, Mohr et al.110 applied Enzyme-Linked Immunosor-
bent Assay (ELISA) towards one of the most prevalent synthetic
cannabinoids in urine, UR-144, and XLR-11. Once again
testing in urine, the method was validated against liquid
chromatography-tandem mass spectrometry with 90 positive
and negative control samples for UR-144, XLR-11 and its
metabolites.
Fig. 3 Visual representation of synthetic cannabinoid presumptive test, reproduced from ref. 99 with permission of Narcotic Testing Supplies &
Equipment Store.
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Miscellaneous
As reported in the introduction, the new psychoactive sub-
stance epidemic is an ever growing market with a vast array of
new materials discovered each year.7 To cover every known sub-
stance is beyond the scope of this review however; in this
section, interesting pieces of research from around the world
will be covered.
Piperazines
N-Benzylpiperazine (BZP), the structure of which is shown in
Scheme 3, is known to be a central nervous system stimulant
with its eﬀects reported to be similar to amphetamine in that
it also triggers the release of dopamine and norepinephrine
whilst inhibiting the uptake of dopamine, norepinephrine and
serotonin.111 Although BZP is structurally similar to amphet-
amine it is reported to have only one-tenth the potency.111
Marketed as a ‘party pill’ before legal restrictions BZP was
viewed as a safe alternative to amphetamines such as
MDMA,112 however recently it has varying degrees of legislative
control internationally.113 Its appearance in “legal high”
samples is still reported114,115 however after being made illegal
the prevalence of its use has declined; for example in New
Zealand after being made a prohibited substance in 2008, the
use of BZP amongst the general population dropped from
15.3% in 2006 to 3.2% in 2009.116
In the UK, the first deaths associated with BZP and
3-TFMPP were three separate fatalities wherein one of both of
the drugs were confirmed to be present although not deter-
mined to be the direct mechanism of death.117 Dickson
et al.118 reported that BZP, 3′-TFMPP and MCPP are present in
ecstasy tablets since the former, in some nations, is a legal
alternative to MDMA. The authors analysed 251 MDMA posi-
tive urine samples using GC-MS via a liquid–liquid extraction
and pentafluoropropionic anhydride (PFPA) derivatisation as
sample pre-treatment to screen for 33 drugs potentially
present.118 In 36% of the sample, drugs other than MDMA
were found to be present; BZP, 3-TFMPP and MCPP were
detected in 15%, 7% and 1% of the samples respectively.118
A wide array of analytical approaches have been reported by
many diﬀerent authors such as LC-MS,24,119 capillary electro-
phoresis,120 HPLC-fluorescence,121 LC with diode array,122,123
GC-MS124–126 and chemiluminescence.127 Arbo and co-
workers128 provided a thorough overview of piperazine com-
pounds as drugs of abuse with the full range of analytical
techniques and matrices applied, readers are directed to this
paper.128
It is clear, something that is generally the case with all
“legal highs”, confirmatory laboratory based analysis is well
developed. Lesser developed, however, are approaches that
could adapted for used in-the-field or within a clinical setting
where a near-instantaneous response is required. To this end,
currently there are no immunoassays for the detection of
piperazines derivatives128 and cross-reactivity of these com-
pounds in fluorescence polarization immunoassay using
AxSYM®, amphetamine/methamphetamine assay has been
reported.129
Recently Philp et al.130 have reported on the development
and validation of a specific colour test using 1′,2′-naphthoquin-
one-4-sulphonate (NQS) forming an intense bright orange-
red complex with BZP at room temperature. The authors
reported that common cutting agents such as glucose and
caﬀeine did not aﬀect the test. 3-TFMPP, MCPP, pCPP, MeOPP
and piperazines produced an orange-red colour change where
the apparent brilliance of the BZP-NQS complex made it appar-
ently to be distinguishable from the other colour changes with
the potential cross-reactants.
Aminoindanes
Aminoindanes are a group of synthetic compounds character-
ised by the presence of a phenethylamine skeleton, they are
currently not controlled globally131 and have more recently
been found to be contained in “legal high” products sold as
powders akin to synthetic cathinones.132,133 2-Aminoindane
Scheme 2 Chemical structures of synthetic cathinones discovered
after legislative bans were introduced: cyclopropylindoles e.g. UR-144,
XLR-11 and adamantylindoles (APICA and APINACA).
Scheme 3 Benzylpiperazine and other piperazines derivatives which
have been historically abused.
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has a basic ring structure that is similar to amphetamine (and
therefore by proxy, substituted cathinones also) that can be
chemically modified and the following derivatives (Scheme 4);
5′,6′-methylenedioxy-2-aminoindane (MDAI), 5′,6′-methyl-
enedioxy-N-methyl-2-aminoindane (MDMAI), 5′-iodo-2-amino-
indane (5-IAI), and 5′-methoxy-6′-methyl-2-aminoindane
(MMAI) have all reportedly been found in “legal highs”.132
A number of aminoindane compounds have been
thoroughly characterized by Casale and Hays134 who provided
analytical protocols in the form of NMR, MS and IR for 5-IAI,
4-IAI, their synthetic intermediates and impurities in order to
assist forensic analysts.134 There is other work that reports a
LC-MS/MS screening method for 26 analytes,34 including
MDAI, and such an approach is designed to provide screening,
within a clinical toxicology setting, for the potential misuse of
“legal highs” via analysis of urine.34
Particularly of note, work by Elie and co-workers reports
that microcrystalline identification of MDAI, mephedrone and
N-benzylpiperazine (BZP) is possible.114 In this protocol the
illicit compound is dissolved into methanol and diluted with
water to produce a content of 10% (v/v) with mercury chloride
(10 g L−1 + 10% methanol) used as the microcrystalline
agent.114 This approach involves dropping 10 μL of the drug
solution with 10 μL of the reagent solution onto a glass slide;
the resulting structures were optically imaged following
assisted nucleation (gently swirling a plastic pipette tip in the
freshly mixed drop).114 Fig. 4 shows the observed crystal struc-
ture which is compared to the crystal structure of illicit drugs.
The MDAI free base (Fig. 4bi) was found to form flat serrated
blades of various dimensions which become irregular with
increasing sizes. Smaller crystals are observed to be single
blades whereas larger crystals develop two dimensional bunch
structures – after drying larger blade crystals are evident. It
was noted that crystals grew within 60 s following assisted
nucleation indicating the potential for a fast presumptive test
strategy.114 The uniqueness of these tests were determined
through comparisons of MDAI structure with a range of illicit
drugs, indicating that potentially this approach is feasible to
identify the MDAI structure in a real sample containing other
illicit drugs. To this end the authors114 purchased “legal high”
samples and utilised their microcrystalline presumptive test
approach which when collaborated with FTIR/GC-MS.
Salvinorin A (Saliva divinorum)
Salvia divinorum is a hallucinogenic psychoactive herb local to
Oaxaca in Central Mexico and for centuries has been used by
cultures indigenous to the region.135,136 This rare member of
the mint family is also known as ‘magic mint’ and more collo-
quially: ‘ska Maria’, ‘ska Pastora’, ‘hierba de Maria’, ‘hojas de
la Pastora’ all names which pertain to the belief that S. divi-
norum is the reincarnation of the Virgin Mary.137 The use of
this plant as a psychoactive substance has spread globally, its
major constituent – salvinorin A (SA) is a known selective
opioid antagonist and to this end emphasis in the literature
has been put on detecting SA.135 A dosage between 200–500 μg
of SA has been found to induce profound hallucinations with
feelings of physical or mental displacement as well as experi-
encing extraordinary illusions.138 Recently studies have pos-
tured SAs eﬀects involve the endocannabinoid system.139
To analyse intact S. divinorum leaves for the presence of SA
there has been the employing of both thin layer chromato-
graphy using desorption electrospray ionization mass
spectrometry (TLC-DESI-MS)140 and thin layer chromatography
teamed with gas chromatography/mass spectrometry (TLC-GS/
MS).141 By utilizing these techniques, the authors of both
techniques were able to confirm the presence of salvinorin
A in a submitted plant material suspected to be Salvia
divinorum.140,141
Pichini and co-workers142 attempted the detection of Salvi-
norin A in diﬀerent biological matrices opposed to the solid
leaf matter. Utilising a gas chromatography mass spectro-
metric protocol, it was applied to detecting SA in plasma,
urine, saliva and sweat.142 Following validation with 17-alpha-
methyltestosterone as an internal standard the method was
applied to the analysis of urine, saliva and sweat from two con-
sumers after smoking 75 mg plant leaves. Salvinorin A was
detected in urine (2.4 and 10.9 ng mL−1) and saliva (11.1 and
25.0 ng mL−1), but not in sweat patches from consumers.142
The quantification of SA in plasma and cerebrospinal fluid
(from a rhesus monkey) has also been attempted and success-
fully completed using a negative ion liquid chromatography-
mass spectrometry atmospheric pressure chemical ionization
(LC-MS/APCI).143 Using the United States Food and Drug
Administration (FDA) guidelines the authors of the method
concluded the technique had a lower limit of quantification
(LLOQ) of 2 ng mL−1 for 0.5 mL of plasma samples over the
linear range 2–1000 ng mL−1.143
Mitragynine (Kratom)
Mitragynine is an indole alkaloid derived from the plant Mitra-
gyna speciosa which is indigenous to Thailand and other
Southeast Asian countries. This is a common “legal high” and
is known commonly as Kratom which is also the chemical’s
Thai name. The leaves of the M. speciosa were historically used
as an opium substitute as well as being used traditionally by
Scheme 4 2-Aminoindane and its derivatives, all of which have been
found in “legal high” samples.
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villages in southern Thailand as a medicine for diarrhoea,
muscle pain and hypertension in addition to also being used
by agricultural workers and labourers to relieve tiredness and
improve eﬃciency.144 Its study remains pertinent as reports of
a fatality associated with Kratom are as recent as 2013.145
Interestingly, mitragynine is the major constituent of
Kratom reported to be 66.2% based on the crude base from the
young leaves.146,147 Levels of mitragynine in adults plants from
Thailand have been reported to be approximately over 60%
whereas in Malaysia only over 10%. Paynantheine and the
mitragynine diastereomer speciogynine were the second most
abundant alkaloids and the mitragynine diastereomer specio-
gynine was the third abundant alkaloid in both plants.148
The pharmacology of mitragynine has been extensively
studied and has been reported to have analgesic activity on the
opioid system.144,149–151 Unlike the case of other NPSs reported
in this review where they have emerged and analytical tech-
niques have had to be developed/invented for their quantifi-
cation, mitragynine, due to its historical use analytical
methods already exist and are generally applied to facilitate
Fig. 4 Microcrystals formed with mercury chloride and (a) mephedrone (c = 10 g L−1), (bi) MDAI freebase (c = 1 g L
−1), (bii) MDAI hydrochloride
(c = 1 g L−1) and (c) BZP (c = 1 g L−1).114 Reproduced from ref. 114 with permission of Elsevier.
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pharmacological studies. To this end, Janchawee144 reported
the first analytical methodology utilising HPLC-UV. A linear
range of 0.1–10 μg mL−1 was reported with a LOD of 0.03 μg
mL−1 and LOQ of 0.1 μg mL−1. Their protocol was applied to
determine the pharmacokinetic characteristic of mitragynine
in the serum of rats following oral administration.
As the leaves of Kratom became sold as “legal highs” in
many other countries Kikura-Hanajiri and colleagues146
reported the detection of mitragynine and 7-OH-mitragynine
(oxidative derivatives of mitragynine)152 in 13 “legal high” pro-
ducts using LC-ESI-MS. The authors found that 11 of the 13
products were found to contain mitragynine and 7-OH-mitra-
gynine with their content found to range from 1 to 6% and in
the latter 0.01 to 0.04%.146 Other researchers have directed
research to study the methods of mitragynine in biological
matrices using LC-MS153–155 and UHPLC-UV.156,157
From inspection of the literature, it is evident that there are
multiple ways for the detection and quantification of Kratom
ingestion/consumption with detection levels as low as 0.02 µg
mL−1.158 For example Arndt and co-workers reported upon a
case of a drug and rehabilitation centre reporting an analysis
for Krypton (another name for Kratom) in the urine of a former
opiate addicted woman.159 The immunological drug screen-
ings were performed with test strips and a cloned enzyme
donor immunoassay wherein alkaloids and tramadol metab-
olites were analysed by LC-MS/MS. The immunoassays yielded
negative responses for amphetamines, barbiturates, benzo-
diazepines, benzoylecgonine, buprenorphine, ethylgluconor-
ide, methadone, opiates, oxycodone and THC-COOH just as
the test strips were negative from tramadol and its metabolites.
The LC-MS/MS detected the alkaloids typically found in
Kratom mitragynine, speciociliatine, speciogynine, mitracilia-
tine and paynantheine – detection of these alkaloids
served suﬃcient proof of Kratom abuse and after confrontation
with data the patient admitted to several infusions of the
plant.159
Conclusion and future challenges
The work described in this review demonstrates the range of
new analytical methods and techniques applied to the detec-
tion and quantification of NPSs, which have recently emerged
on the recreational drugs market. Given the rapidly evolving
nature of the recreational drugs market, in terms of the
number of new substances being identified (101 new sub-
stances, in Europe, in 2014); the ease at which these sub-
stances are available through on-line vendors or “head shops”;
the freely-available information regarding NPS production
and/or pharmacology and the lack of globalised drug/precur-
sor control legislation – makes the current analytical, forensic
and legal challenges clearly apparent. These issues coupled
with the limited availability and range of certified primary
reference standards; fully validated, simple and cheap labora-
tory-based analytical methods and selective and sensitive in-
field testing technology highlights the growing gap in knowl-
edge and necessitates economic investment and focused
research in this underfunded area.
Future advances can be expected in the following areas: (i)
Design and development of miniaturised in-field detection
systems for NPSs in bulk samples or adulterated products
(such as alcoholic drinks); (ii) Rapid, non-evasive bioanalytical
methods for detection of the principle metabolites of common
NPSs; (iii) simple, selective and validated laboratory-based
chromatographic methods for the discrimination of new
psychoactive substances, their isomers and their principle
metabolites in biological matrices and; (iv) impurity profiling
and/or source identification of common NPSs.
Clearly, the “war on drugs” is showing no sign of relenting
in the near future and the principle challenge facing law enfor-
cement agencies is to be ‘one-step-ahead’ of the clandestine
drug manufacturers. By working collectively, analytical che-
mists, policy makers, law enforcement and forensic prac-
titioners can suitably identify potential classes of molecules
that may become the next generation of NPSs and develop
advanced methods/technologies for the simultaneous detec-
tion/quantification of these substances thereby legislating
against potentially dangerous compounds before they pose a
serious threat to human health.
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